AbSci Corp
Vancouver, Washington, United States · Artificial Intelligence, Biopharma, Biotechnology
Absci is a generative AI drug creation company. Our mission is simple: create better biologics for patients, faster. Historically, biologic drug discovery is risky, time-consuming, and expensive, with a >90% failure rate. Instead of looking for the needle in a haystack, we can be creating the needle. If we could reduce our preclinical development timelines and increase our success rate, we could d
Key facts
- Headquarters
- Vancouver, Washington, United States
- Employees
- Unknown
- Industries
- Artificial Intelligence, Biopharma, Biotechnology
- Status
- Public (ABSI)
- Website
- www.absci.com
- Company page
Recent activity at AbSci Corp
- : Absci Corporation Appoints Gerry Muhle as Chief Commercial Officer
- : Eli Lilly led a $100 million funding round for Absci, contributing $40 million to develop ABS-201, an injectable treatment for baldness. The funding aims to enhance their direct-to-consumer ambitions in the growing injectable market.
- : SEC 8-K (8.01): The filing reports that on November 12, 2026, Absci Corporation released a presentation providing updates on its internal pipeline programs. This presentation was distributed to the investment community and is accessible through the 'News & Events' section of the company's website. It serves to inform stakeholders about the company's ongoing projects and strategic direction. The presentation is included as Exhibit 99.2 in the filing.
- : SEC 8-K (2.02): On August 11, 2026, Absci Corporation announced its financial results for the second quarter ending June 30, 2026. The announcement includes key performance metrics that indicate the company's operational performance over the quarter and strategic outlook moving forward. The results are part of an ongoing effort to provide transparency to shareholders and maintain compliance with filing regulations. The financial results may have implications for stockholder value and the company's market positioning.
- : SEC 8-K (8.01): On August 11, 2026, Absci Corporation released a presentation to the investment community which includes updates on its internal pipeline programs. This document is intended to provide stakeholders with an overview of the company's current business status. The presentation is available for access in the 'News & Events' section of the company's website, indicating a commitment to transparency with investors. This filing is significant as it relates to ongoing business updates, highlighting the strategic direction and focus areas of Absci Corporation.
- : SEC 8-K (8.01): On June 24, 2026, Absci Corporation released interim Phase 1 data from the HEADLINE™ Trial of ABS-201. This press release highlights key findings and updates regarding the ongoing clinical trial, which aims to investigate the efficacy and safety of ABS-201 in patients. The announcement is significant for stakeholders as it potentially indicates advancements in the drug development process for this candidate. The information further broadens the corporate narrative surrounding Absci's research innovations in the biotechnology sector.
- : SEC 8-K (1.01): On June 24, 2026, Absci Corporation entered into an underwriting agreement with Jefferies LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC for the issuance and sale of 13,495,277 shares of common stock at an offering price of $7.41 per share. The offering, expected to close on June 25, 2026, is expected to generate net proceeds of approximately $93.5 million, intended for advancing their AI-designed anti-PRLR antibody product candidate ABS-201 and for general corporate purposes. The Underwriting Agreement includes standard representations, warranties, conditions to closing, and indemnification obligations, illustrating a strategic move for funding product development in key therapeutic areas like androgenetic alopecia and endometriosis.
- : SEC 8-K (8.01): On June 24, 2026, Absci Corporation announced the issuance of Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201. This press release highlights important findings related to the clinical trial, potentially impacting the company's research and development strategies. The announcement serves to inform investors and stakeholders of the progress in the trial, enhancing transparency about the company’s ongoing pharmaceutical developments. The press release is filed as Exhibit 99.1 to the Current Report on Form 8-K.
- : SEC 8-K (5.07): On June 4, 2026, Absci Corporation held its Annual Meeting of Stockholders where key decisions were made regarding the board of directors. Stockholders voted to elect Prof. Sir Menelas Pangalos, Ph.D., and Daniel Rabinovitsj as Class II members of the Company's board, to serve until the 2029 Annual Meeting or until their earlier departure. This decision comes in the context of ongoing growth strategies for Absci, as they continue to expand their influence in the biotech industry. The Company had 155,447,428 shares outstanding eligible for voting as of the record date, April 7, 2026.
- : SEC 8-K (8.01): On May 7, 2026, Absci Corporation released a corporate presentation providing updates on its internal pipeline programs. This presentation is part of the Company’s efforts to keep the investment community informed about its business strategies and developments. The document is accessible on the 'News & Events' section of the Company's website, indicating a proactive approach in engaging stakeholders. No specific financial amounts or strategic partnerships were detailed, but the emphasis on pipeline program updates reflects ongoing initiatives that may impact the company's future performance in the industry.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
AbSci Corp funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Funding Round | $40.0M |
| Mar 2021 | Venture | $125.0M |
| Oct 2020 | Venture | $65.0M |
| Jun 2018 | Venture | $12.0M |
| Apr 2016 | Seed | $3.7M |
Leadership
- Afy Okoye, Associate Director, Marketing
- Sean McClain, Executive Officer, Director
- Zach Jonasson, Director
- V. Lawlis, Director
- Ivana Magovcevic-Liebisch, Director
- Gustavo Mahler, Director
- Karen McGinnis, Director
- Andreas Pihl, Director
- Eli Casdin, Director
- Amrit Nagpal, Director
Verified email and direct lines for AbSci Corp’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
AbSci Corp files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to AbSci Corp
- AnHeart Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Therapeutics
- YS Biopharma · Biopharma, Biotechnology, Health Care, Manufacturing, Therapeutics
- Contineum Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Therapeutics
- Innovent Biologics (Innovent) · Biopharma, Biotechnology, Health Care, Manufacturing, Therapeutics
- LakeShore Biopharma Ltd · Biopharma, Biotechnology, Health Care, Manufacturing, Therapeutics
About AbSci Corp: questions and answers
What does AbSci Corp do?
Absci is a generative AI drug creation company. Our mission is simple: create better biologics for patients, faster. Historically, biologic drug discovery is risky, time-consuming, and expensive, with a >90% failure rate. Instead of looking for the needle in a haystack, we can be creating the needle. If we could reduce our preclinical development timelines and increase our success rate, we could d
Where is AbSci Corp headquartered?
AbSci Corp is headquartered in Vancouver, Washington, United States.
Has AbSci Corp raised funding?
Yes. Fundz has recorded 5 funding events for AbSci Corp. The most recent, Funding Round of $40.0M, was in Jul 2026.
What is the latest news on AbSci Corp?
On Nov 12, 2026, Absci Corporation Appoints Gerry Muhle as Chief Commercial Officer
Is AbSci Corp a public company?
Yes. AbSci Corp is publicly traded under the ticker ABSI.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy